BioCentury | Feb 23, 2021
Product Development

Feb. 22 Quick Takes: Sanofi, J&J in COVID vaccine manufacturing deal; plus AZ, Regeneron-Sanofi, Incyte, Ascletis, Novo-Altasciences, Regor

...raised $90 million in a series B financing led by Lilly Asia Ventures with participation from Loyal Valley Capital...
BioCentury | Nov 3, 2020
Product Development

Nov. 2 Quick Takes: EMA reviewing filgotinib and DBV’s peanut allergy therapy; plus Royalty Pharma-CF Foundation, CARSgen, Karyopharm, Aurinia, Regeneron and Astellas

...therapy company CARsgen Therapeutics Co. Ltd. raised $168 million in series C financing led by Loyal Valley Capital...
...Golovin Viaskin Peanut (DBV-712) Jyseleca, filgotinib (GLPG0634, GS-6034) Xpovio, selinexor (ATG-010, KPT-330) Voclosporin ophthalmic solution garetosmab, REGN2477 ASP8374, PTZ-201 CARsgen Therapeutics Co. Ltd. Loyal Valley Capital Lilly...
BioCentury | Oct 24, 2020
Finance

Oct. 23 Quick Takes: RA Capital’s $461M new fund; plus venture rounds for Sirnaomics, 3D Medicines, Zhaoke, Orbus, Araris

...million in a series B financing round jointly led by Hillhouse COFL, TPG Asia and Loyal Valley Capital...
BioCentury | Sep 25, 2020
Finance

Sept. 24 Quick Takes: AveXis vets steer Taysha to IPO; plus Exact Sciences, Monte Rosa, OBiO, Moderna, Immetas and more

...Ltd. raised more than RMB300 million ($44 million) in a series C round led by Loyal Valley Capital...
BioCentury | Jun 10, 2020
Deals

Deals for leading Chinese immuno-oncology companies: Innovent lands Roche as partner; JW raises $100M

...with participation from CR-CP Life Science Fund and Oriza Holdings as well as existing investors Loyal Valley Capital...
BioCentury | Apr 30, 2020
Finance

Shiyu backs Mabwell’s massive series A following close of second fund

...leading Mabwell’s RMB2 billion ($279.1 million) series A financing. Also participating were Oriental Fortune Capital, Loyal Valley Capital...
BioCentury | Apr 4, 2020
Finance

Megarounds for Chinese biopharmas Legend, RemeGen to support late-stage push

...investors Vivo Capital, Janchor Partners, OrbiMed Advisors and Hudson Bay Capital and undisclosed existing investors. Loyal Valley Capital...
BioCentury | Mar 26, 2020
Finance

March 25 Quick Takes: Temasek leads Abbisko’s $70M C round; plus IASO and Regenacy

...from existing investors Qiming Venture Partners, Jianxin Capital, GIC, Lilly Asia Ventures, CICC Capital and Loyal Valley Capital...
BioCentury | Nov 5, 2019
Financial News

Following JV, Sino backs Akeso's $150M series D

...a series D round of about $150 million in the Zhongshan-based cancer and autoimmune company. Loyal Valley Capital...
BioCentury | Mar 21, 2019
Financial News

Qiming backs Abbisko in $42M series B

...Hu said. Also participating in the round were an undisclosed sovereign wealth fund, CICC Capital, Loyal Valley Capital...
Items per page:
1 - 10 of 12
BioCentury | Feb 23, 2021
Product Development

Feb. 22 Quick Takes: Sanofi, J&J in COVID vaccine manufacturing deal; plus AZ, Regeneron-Sanofi, Incyte, Ascletis, Novo-Altasciences, Regor

...raised $90 million in a series B financing led by Lilly Asia Ventures with participation from Loyal Valley Capital...
BioCentury | Nov 3, 2020
Product Development

Nov. 2 Quick Takes: EMA reviewing filgotinib and DBV’s peanut allergy therapy; plus Royalty Pharma-CF Foundation, CARSgen, Karyopharm, Aurinia, Regeneron and Astellas

...therapy company CARsgen Therapeutics Co. Ltd. raised $168 million in series C financing led by Loyal Valley Capital...
...Golovin Viaskin Peanut (DBV-712) Jyseleca, filgotinib (GLPG0634, GS-6034) Xpovio, selinexor (ATG-010, KPT-330) Voclosporin ophthalmic solution garetosmab, REGN2477 ASP8374, PTZ-201 CARsgen Therapeutics Co. Ltd. Loyal Valley Capital Lilly...
BioCentury | Oct 24, 2020
Finance

Oct. 23 Quick Takes: RA Capital’s $461M new fund; plus venture rounds for Sirnaomics, 3D Medicines, Zhaoke, Orbus, Araris

...million in a series B financing round jointly led by Hillhouse COFL, TPG Asia and Loyal Valley Capital...
BioCentury | Sep 25, 2020
Finance

Sept. 24 Quick Takes: AveXis vets steer Taysha to IPO; plus Exact Sciences, Monte Rosa, OBiO, Moderna, Immetas and more

...Ltd. raised more than RMB300 million ($44 million) in a series C round led by Loyal Valley Capital...
BioCentury | Jun 10, 2020
Deals

Deals for leading Chinese immuno-oncology companies: Innovent lands Roche as partner; JW raises $100M

...with participation from CR-CP Life Science Fund and Oriza Holdings as well as existing investors Loyal Valley Capital...
BioCentury | Apr 30, 2020
Finance

Shiyu backs Mabwell’s massive series A following close of second fund

...leading Mabwell’s RMB2 billion ($279.1 million) series A financing. Also participating were Oriental Fortune Capital, Loyal Valley Capital...
BioCentury | Apr 4, 2020
Finance

Megarounds for Chinese biopharmas Legend, RemeGen to support late-stage push

...investors Vivo Capital, Janchor Partners, OrbiMed Advisors and Hudson Bay Capital and undisclosed existing investors. Loyal Valley Capital...
BioCentury | Mar 26, 2020
Finance

March 25 Quick Takes: Temasek leads Abbisko’s $70M C round; plus IASO and Regenacy

...from existing investors Qiming Venture Partners, Jianxin Capital, GIC, Lilly Asia Ventures, CICC Capital and Loyal Valley Capital...
BioCentury | Nov 5, 2019
Financial News

Following JV, Sino backs Akeso's $150M series D

...a series D round of about $150 million in the Zhongshan-based cancer and autoimmune company. Loyal Valley Capital...
BioCentury | Mar 21, 2019
Financial News

Qiming backs Abbisko in $42M series B

...Hu said. Also participating in the round were an undisclosed sovereign wealth fund, CICC Capital, Loyal Valley Capital...
Items per page:
1 - 10 of 12